There’s an important medical milestone offering new hope to people living with multiple myeloma. A groundbreaking CAR-T cell therapy developed by Legend Biotech has now been used to treat more than 10,000 patients worldwide, marking a major step forward in personalized cancer care. This innovative treatment harnesses a patient’s own immune system to fight the disease in a way that’s very different from traditional therapies. Joining us this morning to talk about what this means for patients and the future of cancer treatment is Alan Bash, President of CARVYKTI®, along with Larry Rothschild, a patient who has undergone the therapy and is here to share his personal journey.